Dr. Deborah Galson is an Associate Professor of Medicine, Division of Hematology/Oncology and of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine. She is a member of the University of Pittsburgh Cancer Institute and of the Molecular and Cellular Cancer Biology Program. Dr. Galson also serves as the Director, Pittsburgh Center for Bone & Mineral Research.
Dr. Galson graduated with a BS in Biology/Genetics & Biochemistry from Cornell University in Ithaca, NY. She spent 1 year of her graduate training at the Weizmann Institute of Science in Rehovot, Israel, and the remaining years at Brandeis University in Waltham, MA, where she obtained her PhD in Biology in 1984 and was an American Association of University Women Fellow. From 1984-1990, Dr. Galson was a NIH postdoctoral fellow (NCI) and later postdoctoral associate at the Massachusetts Institute of Technology (MIT) in Cambridge, MA.
Following her postdoc, Dr. Galson was a Visiting Scientist at MIT and also an Instructor of Medicine and later Assistant Professor of Medicine at Harvard Medical School in Boston, MA. Dr. Galson joined the University of Pittsburgh School of Medicine faculty in 2002.
The main theme of Dr. Galson’s research has been to investigate the regulation of differentiation starting from identifying the key transcriptional regulators outwards to reveal the important signal transduction pathways. Her laboratory uses this theme to reveal novel pathways utilized in pathological bone diseases, such as Paget’s disease of bone and Multiple Myeloma bone disease, which may provide new therapeutic targets. Her current studies focus on the:
Mechanism by which Measles virus nucleocapsid protein (MVNP), which contributes to Paget’s disease of bone, activates cellular genes and alters osteoclast differentiation
Mechanism of cooperation between MVNP and p62 (SQSTM1) with pagetic mutations (eg. p62P392L) to generate Paget's lesions
Mechanism by which multiple myeloma suppresses osteoblast differentiation by inducing Gfi1-mediated epigenetic repression of Runx2
Roles of Gfi1 in regulating osteoblast and osteoclast differentiation
Roles of IKK family members TBK1, IKKε, and optineurin in inflammatory bone diseases
Factors affecting epigenetic chromatin structure regulation of gene expression in osteoclast and osteoblast lineage cells in pathological conditions.
Preclinical assessment of the efficacy of targeting pathways with novel roles identified in our studies of inflammatory bone diseases on preserving bone health in mouse myeloma models.
Dr. Galson is a member of several professional and scientific organizations, including, but not limited to:
American Association for Cancer Research (AACR)
American Society for Biochemistry and Molecular Biology (ASBMB)
American Society for Bone and Mineral Research (ASBMR)
American Society of Hematology (ASH)
American Women in Science (AWIS)
She has served as a grant reviewer for the National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), Italian Ministry of Health, DOD Peer Reviewed Medical Research Program (PRMRP), NASA, Dutch Cancer Society, and Leukemia & Lymphoma Research (UK). She is also a reviewer for more than 20 journals, including: Arthritis & Rheumatism, BBA-Molecular Cell Research, Blood, Cancer Research, Hematologica, and the Journal of Bone and Mineral Research.
View a list of Dr. Galson’s publications here.